Glutathione S-Transferase (αGST) Assay



EP148 v1.0

Goals:

Key Steps:

Other Required Materials:

Quantify alpha glutathione S-transferase (αGST) levels from Organ-Chip effluent samples

  • Prepare all reagents, samples, and standards
  • Run the assay
  • Read plate
  • TECO® Alpha GST EIA (DiaPharma Cat No. TE1056)
  • Plate reader
  • Vortex mixer

Introduction

TECO® αGST is an ELISA for the quantitative determination of alpha Glutathione S-Transferase (αGST). GSTs are enzymes that catalyze the conjugation of glutathione to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. The role of GSTs is to detoxify endogenous compounds such as those that enable the breakdown of xenobiotics. High intracellular concentrations of GSTs coupled and released into serum are indicators of hepatocyte injury and toxicity and can be used as biomarkers. They are also used as indicators of renal injury and nephrotoxicity.

Method

Sample type

Organ-Chip effluent

See Emulate Protocol EP124 Effluent Sampling Protocol.

Recommended assay flow rate (Liver-Chip)

30 µL / h

Recommended effluent dilution (Liver-Chip)

No dilution: Samples are loaded neat.

Note: Sample dilution may need to be adjusted further to accommodate for any experimental modifications by the end-user.

Run assay as described on supplier site

https://diapharma.com/product/apoptosis/toxicology/teco-alpha-gst/

Note: Store kit at 2–8 °C immediately upon receipt. Do not freeze.

Expected sample concentration range (Liver-Chip)

1–40 ng / mL

 


 

© Emulate, Inc., 2019. All rights reserved.

Emulate® and the Emulate logo are registered trademarks for Emulate, Inc.

TECO® is a registered trademark for TECOmedical Group, Switzerland.

The technology disclosed in this document may be covered by one or more patents or patent applications owned by or licensed to Emulate, Inc. No license is granted herein. You are solely responsible for determining whether you have all intellectual property rights that are necessary for your intended use of Emulate products or protocols, and whether you are required to obtain any additional intellectual property rights from a third party. Further information is available by contacting Emulate.